17:59 , Oct 12, 2018 |  BC Week In Review  |  Company News

Arbutus falls on HBV program updates

Arbutus Biopharma Corp. (NASDAQ:ABUS) lost $3.09 (34%) to $6 on Oct. 9 after announcing updates for two of its HBV programs. The move translated to a loss of over $170 million in the company's market...
23:50 , Oct 9, 2018 |  BC Extra  |  Clinical News

Arbutus falls on HBV program updates

Arbutus Biopharma Corp. (NASDAQ:ABUS) lost $3.09 (34%) to $6 on Tuesday after announcing updates for two of its HBV programs. The move translated to a loss of over $170 million in the company's market cap. Arbutus...
19:25 , Oct 5, 2018 |  BC Week In Review  |  Company News

Deal adds HBV therapy to Janssen pipeline, validates Arrowhead platform

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) granted Janssen Pharmaceuticals Inc. rights to an HBV candidate for its curative combination toolbox. The deal, worth up to $3.7 billion, is Arrowhead's first billion dollar deal for a platform that...
11:31 , Oct 4, 2018 |  BC Extra  |  Company News

Deal satisfies Janssen HBV strategy, validates Arrowhead platform

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) granted Janssen Pharmaceuticals Inc. rights to an HBV candidate for its curative combination toolbox. The deal, worth up to $3.7 billion, is Arrowhead's first billion dollar deal for a platform that...
22:42 , Sep 21, 2018 |  BioCentury  |  Product Development

Arrowhead refills its quiver

Arrowhead Pharmaceuticals Inc.’s tox blowup in 2016 set back its clinical timelines, but it also prompted the company to bring a more versatile platform online faster than originally planned. Early data from replacement candidates suggest...
15:19 , Sep 14, 2018 |  BC Week In Review  |  Clinical News

Arrowhead's third-generation RNAi shows initial efficacy against HBV

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) reported initial data showing that monthly doses of its third-generation RNAi therapy ARO-HBV reduced circulating hepatitis B surface antigen (HBsAg) levels in a broad population of patients with chronic HBV infection. The...
20:42 , Sep 6, 2018 |  BC Extra  |  Clinical News

Arrowhead's third-generation RNAi shows initial efficacy against HBV

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) gained $5.29 (38%) to $19.39 Thursday after reporting initial data showing that monthly doses of its third-generation RNAi therapy ARO-HBV reduced circulating HBV surface antigen (HBsAg) in a broad population of...
23:21 , Mar 27, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Hepatitis B virus (HBV) Patient sample and mouse studies suggest agonizing OX40 could help treat HBV infection in patient subsets with poor viral clearance, including pediatric patients with acute infection and adults with chronic...
17:24 , Mar 23, 2018 |  BC Week In Review  |  Clinical News

Inovio reports interim Phase I data for HBV candidate

Inovio Pharmaceuticals Inc. (NASDAQ:INO) reported interim data from a Phase I trial showing that HBV candidate INO-1800 was well tolerated and generated virus-specific T cells, including CD8+ killer T cells. The open-label, dose-escalation, international trial enrolled...
23:35 , Feb 1, 2018 |  BC Innovations  |  Translation in Brief

Cloning closer to home

Chinese Academy of Sciences researchers showed epigenetic modification is key for successful cloning of cynomolgus monkeys, overcoming the technical hurdles that have stalled the generation of live non-human primates despite success in 23 other mammalian...